Mirtazapine is one of the most reliably appetite-boosting antidepressants available, and that effect is not a lucky side benefit but a direct consequence of how the drug acts on brain receptors that regulate hunger and satiety. Prescribed primarily for depression, it has earned a secondary reputation in oncology, palliative care, and gastroenterology specifically because it makes people want to eat more. The appetite effect is strong enough that it shows up in healthy volunteers who are not depressed at all, and it has become a go-to option when clinicians need to reverse dangerous weight loss in seriously ill patients.
Why Mirtazapine Makes You Hungry
Mirtazapine belongs to a class called noradrenergic and specific serotonergic antidepressants. Two of its receptor-blocking actions are especially relevant to appetite. First, it blocks histamine H1 receptors in the brain. Histamine normally helps suppress appetite, so blocking it removes a brake on hunger signaling. Second, it blocks serotonin 5-HT2C receptors, which normally promote the feeling of fullness after eating. Knock those out and the “I’ve had enough” signal gets weaker, pushing you to eat more and especially to crave carbohydrates and sweets.1PubMed Central. Weight-gain independent effect of mirtazapine on fasting plasma lipids in healthy men
A controlled study in healthy men who were not depressed and whose diets were carefully standardized found that after taking mirtazapine for just seven days, hunger ratings and appetite for sweet foods increased, even though the participants were not eating more freely. The drug also shifted how their bodies burned fuel, favoring carbohydrates over fat.2PubMed Central. Effect of mirtazapine on metabolism and energy substrate partitioning in healthy men That study is useful because it separates the drug’s direct appetite effect from the mood-related appetite changes you would see in someone recovering from depression. Mirtazapine makes you hungrier regardless of whether you were depressed to begin with.
Appetite Stimulation in Cancer Patients
Loss of appetite is one of the most distressing and dangerous symptoms for people with advanced cancer. Anorexia-cachexia syndrome, in which patients lose their drive to eat and their muscles waste away, affects a large share of people with advanced malignancies and directly worsens survival. This is where mirtazapine has drawn serious clinical attention.
A randomized trial in patients with non-small-cell lung cancer and documented anorexia found that after four weeks, people taking mirtazapine consumed roughly 380 additional calories per day compared to baseline, with meaningful increases in protein, carbohydrate, and fat intake. By eight weeks, the proportion of patients classified as sarcopenic (having dangerously low muscle mass) dropped from about 83% to 57% in the mirtazapine group.3JAMA Oncology. Mirtazapine as Appetite Stimulant in Patients With Non–Small Cell Lung Cancer and Anorexia: A Randomized Clinical Trial That is a meaningful clinical win, because preserving muscle mass in cancer patients is tied to better tolerance of chemotherapy and longer survival.
A head-to-head trial comparing mirtazapine with olanzapine in patients with advanced oral cavity cancer found that both drugs boosted appetite scores, but mirtazapine had a stronger effect. At two weeks, appetite scores improved more in the mirtazapine group, and by four weeks the gap had widened further. Neither drug produced major weight gain in this population, but the appetite improvement itself mattered for quality of life, sleep, and mood.4PubMed. Comparison of Effectivity and Safety of Olanzapine and Mirtazapine on Cancer-Associated Anorexia and Cachexia in Advanced Oral Cavity Cancer Patients
How Mirtazapine Compares to Megestrol Acetate
Megestrol acetate, a synthetic hormone, has been a standard appetite stimulant in oncology for years. When mirtazapine has been tested against it, the picture is mixed. One randomized double-blind trial found that megestrol produced appetite improvement in a larger proportion of patients (about 92% versus 56% for mirtazapine at eight weeks).5PubMed Central. Mirtazapine versus Megestrol in the Treatment of Anorexia–Cachexia Syndrome in Patients with Advanced Cancer Another randomized trial, however, concluded that mirtazapine showed similar efficacy to megestrol and could serve as a viable alternative.6PubMed. Mirtazapine versus megestrol acetate in treatment of anorexia-cachexia in advanced cancer patients
The practical advantage of mirtazapine over megestrol is its side-effect profile. Megestrol carries risks of blood clots, fluid retention, and adrenal suppression. Mirtazapine brings sedation and potential lipid changes, but for patients who also need help with depression, insomnia, or nausea, it can address multiple problems at once. Clinicians increasingly view mirtazapine as a reasonable first-line option when the patient has depression alongside poor appetite, reserving megestrol for cases where appetite stimulation alone is the priority.
Functional Dyspepsia and Early Fullness
Cancer is not the only reason someone might need help eating more. Functional dyspepsia, a condition where the stomach feels full, painful, or nauseated after eating without any obvious structural cause, can lead to significant weight loss. Mirtazapine has shown real promise here. In a study of patients with functional dyspepsia and weight loss, mirtazapine improved nutrient tolerance from about 543 to 704 calories in a single test meal at eight weeks. Patients also gained roughly four kilograms over that period, and their early-fullness scores dropped significantly.7Clinical Gastroenterology and Hepatology. Efficacy of Mirtazapine in Patients With Functional Dyspepsia and Weight Loss
The mechanism here likely involves more than just appetite stimulation. Mirtazapine affects serotonin receptors in the gut that influence gastric motility and sensitivity. By dampening the stomach’s overreaction to food, it can reduce the nausea and discomfort that keep people from eating adequate portions. For someone whose weight loss stems not from lack of hunger but from feeling miserable when they try to eat, this anti-nausea and gastric-relaxation effect can be more important than the appetite drive itself.
Eating Disorders and Restrictive Intake
Mirtazapine has drawn interest in the treatment of anorexia nervosa and avoidant/restrictive food intake disorder. Its appetite-boosting, anti-nausea, and gastric-emptying effects make it theoretically attractive for patients who struggle with eating.8PubMed. Mirtazapine and Weight Gain in Avoidant and Restrictive Food Intake Disorder A published case report described a patient with anorexia nervosa and depression who gained 2.5 kilograms over three months and achieved full remission of depression within six weeks on mirtazapine.9PubMed. Mirtazapine for anorexia nervosa with depression
The evidence here remains thin. Case reports and small series are not the same as randomized trials, and eating disorders involve complex psychological dimensions that a pill alone cannot address. Clinicians sometimes prescribe mirtazapine as one component of a broader treatment plan, particularly when a patient has co-occurring depression or severe anxiety around eating. It is not a standalone treatment for anorexia nervosa, but it can help nudge the physiological needle in the right direction while other therapies address the underlying psychological drivers.
How Much Weight Gain to Expect
If you are taking mirtazapine for depression and wondering whether the appetite boost will lead to unwanted weight gain, the answer is: often yes, but the magnitude varies. A large meta-analysis of over 450,000 individuals found that mirtazapine was one of the antidepressants most strongly associated with weight gain, alongside tricyclics and certain SSRIs. The average increase was about 1.7 kilograms during the first 12 weeks of treatment.10PubMed Central. Impact of Antidepressants on Weight Gain: Underlying Mechanisms and Mitigation Strategies That average masks wide individual variation, though. Some people gain considerably more, and a minority gain nothing.
The appetite boost and weight gain are dose-related and also depend on what you were eating before. Someone who was severely depressed and barely eating may gain weight rapidly once their appetite recovers, while someone who was already eating normally may gain more modestly. The sedating effect of mirtazapine, which is strongest at lower doses, can also contribute to weight gain by reducing activity levels and promoting late-night snacking. People frequently report intense cravings for carbohydrate-rich and sweet foods, consistent with the drug’s pharmacological profile.
The Appetite Effect Versus the Antidepressant Effect
An interesting wrinkle in the mirtazapine story involves how its appetite stimulation interacts with how clinicians measure depression improvement. A patient-level meta-analysis comparing mirtazapine with SSRIs found that mirtazapine appeared to outperform SSRIs on overall depression rating scales. But when the researchers broke the scales down item by item, the advantage came almost entirely from items related to sleep, appetite, and gastrointestinal symptoms. On the items measuring core depressive symptoms like depressed mood, suicidal thoughts, and anxiety, SSRIs and venlafaxine were actually more effective.11eClinicalMedicine. Impact of sedative and appetite-increasing properties on the apparent antidepressant efficacy of mirtazapine, selective serotonin reuptake inhibitors and amitriptyline
This does not mean mirtazapine is a bad antidepressant. It means that the appetite and sleep effects are so powerful that they inflate the drug’s apparent superiority on standard depression questionnaires. For patients whose depression is closely tied to poor sleep and weight loss, this is arguably an advantage. For someone whose primary symptoms are persistent sadness and anxiety without appetite disruption, an SSRI may address the core problem more directly.
Metabolic Effects Beyond Just Eating More
Mirtazapine’s influence on metabolism extends beyond appetite. Even in the absence of significant weight gain, the drug appears to directly affect how the body handles fats. A study in healthy men given mirtazapine for seven days under strict dietary control, where participants actually lost a small amount of weight, still found unfavorable changes in triglyceride levels and the triglyceride-to-HDL cholesterol ratio.1PubMed Central. Weight-gain independent effect of mirtazapine on fasting plasma lipids in healthy men A separate study in healthy volunteers found that total cholesterol rose significantly by week four and triglycerides spiked early before normalizing.12PubMed. The effects of mirtazapine on plasma lipid profiles in healthy subjects
For most people taking mirtazapine short-term or at low doses, these lipid shifts are modest and may not be clinically meaningful. But there have been case reports of dramatic dyslipidemia in individual patients, including one elderly woman who developed massive lipid elevations on mirtazapine.13PubMed. Mirtazapine-induced massive dyslipidaemia in an elderly woman If you are already managing high cholesterol or triglycerides, your doctor should monitor your lipids after starting mirtazapine. The takeaway is that the drug does something to lipid metabolism directly, not just through making you eat more.
What Happens When You Stop
If mirtazapine was prescribed specifically for appetite stimulation rather than depression, there is a natural question about what happens when you stop taking it. A published case report described a 53-year-old man prescribed mirtazapine at 15 milligrams daily for appetite who inadvertently stopped the drug abruptly. He developed anxiousness, nausea, tremor, loss of appetite, and lost eight pounds.14PubMed. The Hunger for Mirtazapine: A Discontinuation Syndrome This is consistent with the broader pattern of antidepressant discontinuation syndrome, where sudden withdrawal can temporarily produce the very symptoms the drug was treating, and then some.
Tapering off gradually, rather than stopping cold, is the standard recommendation. For someone who was taking mirtazapine primarily for appetite, the loss-of-appetite rebound can be frustrating and even medically risky if they are already underweight. Discuss a tapering plan with your prescriber, especially if you are using the drug in a palliative or weight-recovery context where appetite loss could set you back significantly.
A Surprising Second Career in Veterinary Medicine
Mirtazapine’s appetite effects have crossed the species barrier. Veterinarians now routinely use it to stimulate appetite in cats with chronic kidney disease, cancer, and other conditions that cause dangerous weight loss. A transdermal ointment applied to the ear has become popular because it is easier to administer than a pill. In a survey of cat owners, 77% reported that transdermal mirtazapine effectively stimulated their cat’s appetite, and among those who used it for two weeks or longer, the success rate climbed to about 94%.15PubMed Central. Owner’s Perspective About the Use of Mirtazapine Transdermal Ointment in Cats—A Survey-Based Study
In dogs, the evidence is newer but encouraging. A combined retrospective and prospective study found that dogs treated with mirtazapine were about three times more likely to resume eating voluntarily compared to untreated controls. In a placebo-controlled arm, every dog given mirtazapine accepted food on the first day, versus about 64% of the placebo group. The drug was well tolerated even in dogs with other health problems.16PubMed Central. Evaluation of the Short-Term Effects of Mirtazapine on Appetite Stimulants in Dogs The fact that mirtazapine works across mammalian species reinforces that its appetite effect is pharmacologically robust, not simply a byproduct of mood improvement in humans.
The Low-Dose Sedation Quirk
One counterintuitive feature of mirtazapine worth knowing about: its sedating effect is actually stronger at lower doses (like 7.5 or 15 milligrams) than at higher doses (30 or 45 milligrams). At lower doses, the histamine-blocking effect dominates, producing drowsiness and strong appetite stimulation. As the dose increases, noradrenergic activation kicks in and partially counteracts the sedation. This is why mirtazapine is sometimes prescribed at lower doses specifically when sleep and appetite are the primary targets. Patients and doctors who expect a higher dose to mean stronger appetite stimulation may find the relationship is not so straightforward.
This pharmacological quirk also explains why some people prescribed mirtazapine at a starting dose gain weight rapidly and then stabilize as their dose is increased for depression. The appetite and sedation effects front-load at the beginning of treatment. If you experience intense food cravings and drowsiness in the first few weeks, that does not necessarily predict what the drug will feel like once you reach a therapeutic antidepressant dose.
Who Should and Should Not Rely on It for Appetite
Mirtazapine occupies a useful niche as an appetite stimulant that also treats depression, insomnia, and nausea. It is a strong option when poor appetite is tangled up with one or more of those conditions, as is common in cancer, chronic illness, and severe depression. For someone who needs pure appetite stimulation without the sedation or mood effects, other options like megestrol or dronabinol may be more targeted.
People with metabolic syndrome, poorly controlled diabetes, or existing dyslipidemia should weigh the metabolic risks carefully. The drug’s effects on blood lipids appear to happen independently of weight gain, meaning even a short course could move cholesterol and triglyceride numbers in the wrong direction for someone already at cardiovascular risk. On the other hand, for an underweight patient with cancer-related anorexia, a modest bump in triglycerides is a trivial concern compared to the benefit of eating 380 more calories a day and preserving muscle mass. The context shapes whether mirtazapine’s appetite effect is a feature or a side effect that needs managing.